Literature DB >> 24404420

Replenish the source within: Rescuing tumor-infiltrating lymphocytes by double checkpoint blockade.

Jaikumar Duraiswamy1, Gordon Freeman2, George Coukos3.   

Abstract

We have recently reported that the PD-1 and CTLA4 signaling pathways are active in both effector and regulatory T cells, causing profound immune dysfunctions in the tumor microenvironment. In line with this notion, the dual blockade of PD-1- and CTLA4-conveyed signals may exert robust therapeutic effects. Here, we discuss the mechanisms possibly underlying such a synergic interaction.

Entities:  

Keywords:  CTLA4; PD-1; regulatory T cells; tumor-infiltrating lymphocytes; vaccine

Year:  2013        PMID： 24404420      PMCID： PMC3879129          DOI： 10.4161/onci.25912

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Strength of PD-1 signaling differentially affects T-cell effector functions.

Authors:  Fang Wei; Shi Zhong; Zhengyu Ma; Hong Kong; Andrew Medvec; Rafi Ahmed; Gordon J Freeman; Michelle Krogsgaard; James L Riley
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-22       Impact factor: 11.205

2.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors:  Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

3.  Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.

Authors:  Mark J Selby; John J Engelhardt; Michael Quigley; Karla A Henning; Timothy Chen; Mohan Srinivasan; Alan J Korman
Journal:  Cancer Immunol Res       Date:  2013-04-07       Impact factor: 11.151

Review 4.  GM-CSF-secreting melanoma vaccines.

Authors:  Glenn Dranoff
Journal:  Oncogene       Date:  2003-05-19       Impact factor: 9.867

5.  PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells.

Authors:  Wenshi Wang; Roy Lau; Daohai Yu; Weiwei Zhu; Alan Korman; Jeffrey Weber
Journal:  Int Immunol       Date:  2009-08-03       Impact factor: 4.823

6.  Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.

Authors:  Junzo Hamanishi; Masaki Mandai; Masashi Iwasaki; Taku Okazaki; Yoshimasa Tanaka; Ken Yamaguchi; Toshihiro Higuchi; Haruhiko Yagi; Kenji Takakura; Nagahiro Minato; Tasuku Honjo; Shingo Fujii
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-21       Impact factor: 11.205

7.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

8.  Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

Authors:  Jaikumar Duraiswamy; Karen M Kaluza; Gordon J Freeman; George Coukos
Journal:  Cancer Res       Date:  2013-04-30       Impact factor: 12.701

9.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

10.  PD-L1 regulates the development, maintenance, and function of induced regulatory T cells.

Authors:  Loise M Francisco; Victor H Salinas; Keturah E Brown; Vijay K Vanguri; Gordon J Freeman; Vijay K Kuchroo; Arlene H Sharpe
Journal:  J Exp Med       Date:  2009-12-14       Impact factor: 14.307
  10 in total
  3 in total

1.  Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8+ T cells.

Authors:  Lelisa F Gemta; Peter J Siska; Marin E Nelson; Xia Gao; Xiaojing Liu; Jason W Locasale; Hideo Yagita; Craig L Slingluff; Kyle L Hoehn; Jeffrey C Rathmell; Timothy N J Bullock
Journal:  Sci Immunol       Date:  2019-01-25

Review 2.  Trial Watch: Peptide-based anticancer vaccines.

Authors:  Jonathan Pol; Norma Bloy; Aitziber Buqué; Alexander Eggermont; Isabelle Cremer; Catherine Sautès-Fridman; Jérôme Galon; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-01-09       Impact factor: 8.110

3.  CpG-ODN Facilitates Effective Intratracheal Immunization and Recall of Memory against Neoantigen-Expressing Alveolar Cells.

Authors:  Mathias Riehn; Marcin Cebula; Hansjörg Hauser; Dagmar Wirth
Journal:  Front Immunol       Date:  2017-09-29       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.